Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes
Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Type 1diabetes (T1D) is caused by autoimmune destruction of the pancreatic islet ß-cells,
leading to an absolute deficiency in insulin.
In health, regulatory T cells (Tregs) suppress immune responses against normal tissues, and
likewise prevent autoimmune diseases. Tregs are insufficient in T1D.
The investigators previously showed that administration of low doses of IL-2 induces
selective expansion and activation of Tregs in mice and humans.
The investigators hypothesize that Tregs expansion and activation with low doses of IL2 could
block the ongoing autoimmune destruction of insulin producing cells in patients with recently
diagnosed T1D.